Abstract Treatment of neuropathic pain remains inadequate despite the elucidation of
multiple pathophysiological mechanisms and the development of promising therapeutic …

Traditionally, neurophysiology is the primary diagnostic and prognostic biomarker in
peripheral neuropathy clinical practice; however, it may lack responsiveness in the context …

Aims/hypothesis No established blood-based biomarker exists to monitor diabetic
sensorimotor polyneuropathy (DSPN) and evaluate treatment response. The neurofilament …

Introduction Plasma neurofilament light chain (NfL) is a potential biomarker for
neurodegeneration in Alzheimer's disease (AD), ischemic stroke, and non‐dementia cohorts …

Importance Peripheral neuropathies are common conditions and can result in numbness,
paresthesia, motor deficits, and pain. There is increasing evidence for the use of biomarkers …

OBJECTIVE To investigate the longitudinal development of neurofilament light chain (NfL)
levels in type 2 diabetes with and without diabetic polyneuropathy (+/− DPN) and to explore …

Distal symmetric diabetic peripheral polyneuropathy (DPN) is the most common form of
neuropathy in the world, affecting 30 to 50% of diabetic individuals and resulting in …

High glucose induces Schwann cells death and neurotoxicity. Formononetin was originally
found in Astragalus membranaceus and showed anti-tumor and anti-neuroinflammation …

Background Detecting peripheral neuropathy (PNP) is crucial in preventing complications
such as foot ulceration. Clinical examinations for PNP are infrequently provided to patients …

Introduction Serum neurofilament light chain (sNfL) is an emerging biomarker of neuronal
damage in several neurological disorders. Its association with cognitive function in the …